Epigenetic contributions in the development of rheumatoid arthritis

Arthritis Research and Therapy

Volumn 14, Issue 6, 2012, Pages

  Klein, Kerstin ^a   Ospelt, Caroline ^a   Gay, Steffen ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CPG OLIGODEOXYNUCLEOTIDE; DNA METHYLTRANSFERASE 1; GENOMIC DNA; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 6; CYTOKINE; HISTONE;

CELL TYPE; CPG ISLAND; CYTOKINE RELEASE; DNA METHYLATION; DNA MODIFICATION; EPIGENETICS; HISTONE ACETYLATION; HISTONE METHYLATION; PROTEIN EXPRESSION; RESIDENT SYNOVIAL FIBROBLAST; REVIEW; RHEUMATOID ARTHRITIS; SUMOYLATION; BIOLOGICAL MODEL; FIBROBLAST; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PROTEIN PROCESSING; SYNOVIUM;

ARTHRITIS, RHEUMATOID; CYTOKINES; DNA METHYLATION; EPIGENESIS, GENETIC; FIBROBLASTS; HISTONES; HUMANS; MODELS, GENETIC; PROTEIN PROCESSING, POST-TRANSLATIONAL; SYNOVIAL MEMBRANE;

EID: 84870291587     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4074     Document Type: Review

References (52)

1. Smolen J, Aletaha D. The burden of rheumatoid arthritis and access to treatment: a medical overview. Eur J Health Econ 2008, 8(Suppl 2):S39-S47.
2. Padyukov L, Seielstad M, Ong RT, Ding B, Ronnelid J, Seddighzadeh M, Alfredsson L, Klareskog L. A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann Rheum Dis 2011, 70:259-265. 10.1136/ard.2009.126821, 3015094, 21156761.
3. Saevarsdottir S, Wallin H, Seddighzadeh M, Ernestam S, Geborek P, Petersson IF, Bratt J, van Vollenhoven RF. Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. Ann Rheum Dis 2011, 70:469-475. 10.1136/ard.2010.139212, 21149498.
4. Lefèvre S, Knedla A, Tennie C, Kampmann A, Wunrau C, Dinser R, Korb A, Schnaker EM, Tarner IH, Robbins PD, Evans CH, Stürz H, Steinmeyer J, Gay S, Schölmerich J, Pap T, Müller-Ladner U, Neumann E. Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat Med 2009, 15:1414-1420. 10.1038/nm.2050, 19898488.
5. Ospelt C, Gay S. The role of resident synovial cells in destructive arthritis. Best Pract Res Clin Rheumatol 2008, 22:239-252. 10.1016/j.berh.2008.01.004, 18455682.
6. Bird A. Perceptions of epigenetics. Nature 2007, 447:396-398. 10.1038/nature05913, 17522671.
7. Turek-Plewa J, Jagodzinski PP. The role of mammalian DNA methyltransferases in the regulation of gene expression. Cell Mol Biol Lett 2005, 10:631-647.
8. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000, 403:41-45. 10.1038/47412, 10638745.
9. Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet 2008, 9:465-476.
10. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 2012, 13:484-492. 10.1038/nrg3230, 22641018.
11. Neidhart M, Rethage J, Kuchen S, Kunzler P, Crowl RM, Billingham ME, Gay RE, Gay S. Retrotransposable L1 elements expressed in rheumatoid arthritis synovial tissue: association with genomic DNA hypomethylation and influence on gene expression. Arthritis Rheum 2000, 43:2634-2647. 10.1002/1529-0131(200012)43:12<2634::AID-ANR3>3.0.CO;2-1, 11145021.
12. Karouzakis E, Gay RE, Michel BA, Gay S, Neidhart M. DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2009, 60:3613-3622. 10.1002/art.25018, 19950268.
13. Karouzakis E, Gay RE, Gay S, Neidhart M. Increased recycling of polyamines is associated with global DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2012, 64:1809-1817. 10.1002/art.34340, 22170508.
14. Liu CC, Fang TJ, Ou TT, Wu CC, Li RN, Lin YC, Lin CH, Tsai WC, Liu HW, Yen JH. Global DNA methylation, DNMT1, and MBD2 in patients with rheumatoid arthritis. Immunol Lett 2011, 135:96-99. 10.1016/j.imlet.2010.10.003, 20937307.
15. Karouzakis E, Rengel Y, Jungel A, Kolling C, Gay RE, Michel BA, Tak PP, Gay S, Neidhart M, Ospelt C. DNA methylation regulates the expression of CXCL12 in rheumatoid arthritis synovial fibroblasts. Genes Immun 2011, 12:643-652. 10.1038/gene.2011.45, 21753787.
16. Nile CJ, Read RC, Akil M, Duff GW, Wilson AG. Methylation status of a single CpG site in the IL6 promoter is related to IL6 messenger RNA levels and rheumatoid arthritis. Arthritis Rheum 2008, 58:2686-2693. 10.1002/art.23758, 18759290.
17. Ishida K, Kobayashi T, Ito S, Komatsu Y, Yokoyama T, Okada M, Abe A, Murasawa A, Yoshie H. Interleukin-6 gene promoter methylation in rheumatoid arthritis and chronic periodontitis. J Periodontol 2012, 83:917-925. 10.1902/jop.2011.110356, 22122521.
18. Fu LH, Ma CL, Cong B, Li SJ, Chen HY, Zhang JG. Hypomethylation of proximal CpG motif of interleukin-10 promoter regulates its expression in human rheumatoid arthritis. Acta Pharmacol Sin 2011, 32:1373-1380. 10.1038/aps.2011.98, 21986577.
19. Lin SY, Hsieh SC, Lin YC, Lee CN, Tsai MH, Lai LC, Chuang EY, Chen PC, Hung CC, Chen LY, Hsieh WS, Niu DM, Su YN, Ho HN. A whole genome methylation analysis of systemic lupus erythematosus: hypomethylation of the IL10 and IL1R2 promoters is associated with disease activity. Genes Immun 2012, 13:214-220. 10.1038/gene.2011.74, 22048455.
20. Takami N, Osawa K, Miura Y, Komai K, Taniguchi M, Shiraishi M, Sato K, Iguchi T, Shiozawa K, Hashiramoto A, Shiozawa S. Hypermethylated promoter region of DR3, the death receptor 3 gene, in rheumatoid arthritis synovial cells. Arthritis Rheum 2006, 54:779-787. 10.1002/art.21637, 16508942.
21. Stanczyk J, Ospelt C, Karouzakis E, Filer A, Raza K, Kolling C, Gay R, Buckley CD, Tak PP, Gay S, Kyburz D. Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation. Arthritis Rheum 2011, 63:373-381. 10.1002/art.30115, 3116142, 21279994.
22. Niederer F, Trenkmann M, Ospelt C, Karouzakis E, Neidhart M, Stanczyk J, Kolling C, Gay RE, Detmar M, Gay S, Jüngel A, Kyburz D. Downregulation of microRNA-34a* in rheumatoid arthritis synovial fibroblasts promotes apoptosis resistance. Arthritis Rheum 2012, 64:1771-1779. 10.1002/art.34334, 22161761.
23. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297. 10.1016/S0092-8674(04)00045-5, 14744438.
24. Filkova M, Jungel A, Gay RE, Gay S. MicroRNAs in rheumatoid arthritis: potential role in diagnosis and therapy. BioDrugs 2012, 26:131-141. 10.2165/11631480-000000000-00000, 22494429.
25. Chabchoub G, Uz E, Maalej A, Mustafa CA, Rebai A, Mnif M, Bahloul Z, Farid NR, Ozcelik T, Ayadi H. Analysis of skewed X-chromosome inactivation in females with rheumatoid arthritis and autoimmune thyroid diseases. Arthritis Res Ther 2009, 11:R106. 10.1186/ar2759, 2745787, 19589151.
26. Wang Z, Zang C, Cui K, Schones DE, Barski A, Peng W, Zhao K. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 2009, 138:1019-1031. 10.1016/j.cell.2009.06.049, 2750862, 19698979.
27. Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I, Coombes RC. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res 2001, 7:971-976.
28. Jungel A, Baresova V, Ospelt C, Simmen BR, Michel BA, Gay RE, Gay S, Seemayer CA, Neidhart M. Trichostatin A sensitises rheumatoid arthritis synovial fibroblasts for TRAIL-induced apoptosis. Ann Rheum Dis 2006, 65:910-912. 1798225, 16284094.
29. Nishida K, Komiyama T, Miyazawa S, Shen ZN, Furumatsu T, Doi H, Yoshida A, Yamana J, Yamamura M, Ninomiya Y, Inoue H, Asahara H. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum 2004, 50:3365-3376. 10.1002/art.20709, 15476220.
30. Grabiec AM, Krausz S, de Jager W, Burakowski T, Groot D, Sanders ME, Prakken BJ, Maslinski W, Eldering E, Tak PP, Reedquist KA. Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. J Immunol 2010, 184:2718-2728. 10.4049/jimmunol.0901467, 20100935.
31. Grabiec AM, Korchynskyi O, Tak PP, Reedquist KA. Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. Ann Rheum Dis 2012, 71:424-431. 10.1136/ard.2011.154211, 3277722, 21953341.
32. Lin HS, Hu CY, Chan HY, Liew YY, Huang HP, Lepescheux L, Bastianelli E, Baron R, Rawadi G, Clement-Lacroix P. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol 2007, 150:862-872. 10.1038/sj.bjp.0707165, 2013883, 17325656.
33. Nasu Y, Nishida K, Miyazawa S, Komiyama T, Kadota Y, Abe N, Yoshida A, Hirohata S, Ohtsuka A, Ozaki T. Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. Osteoarthritis Cartilage 2008, 16:723-732. 10.1016/j.joca.2007.10.014, 18226559.
34. Saouaf SJ, Li B, Zhang G, Shen Y, Furuuchi N, Hancock WW, Greene MI. Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. Exp Mol Pathol 2009, 87:99-104. 10.1016/j.yexmp.2009.06.003, 2753738, 19577564.
35. Joosten LA, Leoni F, Meghji S, Mascagni P. Inhibition of HDAC activity by ITF2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis. Mol Med 2011, 17:391-396. 10.1007/s00894-010-0739-z, 3105133, 21327299.
36. Huber LC, Brock M, Hemmatazad H, Giger OT, Moritz F, Trenkmann M, Distler JH, Gay RE, Kolling C, Moch H, Michel BA, Gay S, Distler O, Jüngel A. Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients. Arthritis Rheum 2007, 56:1087-1093. 10.1002/art.22512, 17393417.
37. Horiuchi M, Morinobu A, Chin T, Sakai Y, Kurosaka M, Kumagai S. Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts. J Rheumatol 2009, 36:1580-1589. 10.3899/jrheum.081115, 19531758.
38. Kawabata T, Nishida K, Takasugi K, Ogawa H, Sada K, Kadota Y, Inagaki J, Hirohata S, Ninomiya Y, Makino H. Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis. Arthritis Res Ther 2010, 12:R133. 10.1186/ar3071, 2945023, 20609223.
39. Grabiec AM, Reedquist KA. Histone deacetylases in RA: epigenetics and epiphenomena. Arthritis Res Ther 2010, 12:142. 10.1186/ar3137, 2991004, 20959025.
40. Gillespie J, Savic S, Wong C, Hempshall A, Inman M, Emery P, Grigg R, McDermott MF. Histone deacetylases are dysregulated in rheumatoid arthritis and a novel histone deacetylase 3-selective inhibitor reduces interleukin-6 production by peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Rheum 2012, 64:418-422. 10.1002/art.33382, 21952924.
41. Maciejewska-Rodrigues H, Karouzakis E, Strietholt S, Hemmatazad H, Neidhart M, Ospelt C, Gay RE, Michel BA, Pap T, Gay S, Jüngel A. Epigenetics and rheumatoid arthritis: the role of SENP1 in the regulation of MMP-1 expression. J Autoimmun 2010, 35:15-22. 10.1016/j.jaut.2009.12.010, 20079608.
42. Niederer F, Ospelt C, Brentano F, Hottiger MO, Gay RE, Gay S, Detmar M, Kyburz D. SIRT1 overexpression in the rheumatoid arthritis synovium contributes to proinflammatory cytokine production and apoptosis resistance. Ann Rheum Dis 2011, 70:1866-1873. 10.1136/ard.2010.148957, 21742641.
43. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128:693-705. 10.1016/j.cell.2007.02.005, 17320507.
44. Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature 2011, 469:343-349. 10.1038/nature09784, 21248841.
45. Trenkmann M, Brock M, Gay RE, Kolling C, Speich R, Michel BA, Gay S, Huber LC. Expression and function of EZH2 in synovial fibroblasts: epigenetic repression of the Wnt inhibitor SFRP1 in rheumatoid arthritis. Ann Rheum Dis 2011, 70:1482-1488. 10.1136/ard.2010.143040, 21515604.
46. Meinecke I, Cinski A, Baier A, Peters MA, Dankbar B, Wille A, Drynda A, Mendoza H, Gay RE, Hay RT, Ink B, Gay S, Pap T. Modification of nuclear PML protein by SUMO-1 regulates Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts. Proc Natl Acad Sci USA 2007, 104:5073-5078. 10.1073/pnas.0608773104, 1829266, 17360386.
47. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007, 25:84-90. 10.1038/nbt1272, 17211407.
48. Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, Tanaka A, Komatsu Y, Nishino N, Yoshida M, Horinouchi S. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002, 62:4916-4921.
49. Golay J, Cuppini L, Leoni F, Mico C, Barbui V, Domenghini M, Lombardi L, Neri A, Barbui AM, Salvi A, Pozzi P, Porro G, Pagani P, Fossati G, Mascagni P, Introna M, Rambaldi A. The histone deacetylase inhibitor ITF2357 has antileukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia 2007, 21:1892-1900. 10.1038/sj.leu.2404860, 17637810.
50. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001, 20:6969-6978. 10.1093/emboj/20.24.6969, 125788, 11742974.
51. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T, Nakanishi O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 1999, 96:4592-4597. 10.1073/pnas.96.8.4592, 16377, 10200307.
52. Giammona LM, Panuganti S, Kemper JM, Apostolidis PA, Lindsey S, Papoutsakis ET, Miller WM. Mechanistic studies on the effects of nicotinamide on megakaryocytic polyploidization and the roles of NAD+ levels and SIRT inhibition. Exp Hematol 2009, 37:1340-1352. 10.1016/j.exphem.2009.08.004, 2763937, 19715739.